Fig. 2.

Patient disposition. ^aThe safety population included all patients who were randomized and received at least one dose of study drug. ^bThe FAS included all patients who were randomized and received at least one dose of study drug. One patient was randomized to ATX but, owing to a drug dispensing error, received LDX. Based on the intent-to-treat principle, this patient was included in the ATX treatment group in the FAS. ^cStudy completers were patients who completed visits 0–10 (visit 10 being a clinic visit or telephone call). ^dOther reasons for discontinuation among patients administered LDX were difficulty swallowing capsule (n = 1); early termination requested by the sponsor because of previous marijuana use (n = 1); and early termination requested by the sponsor because patient was unable to meet the study visit schedule (n = 1). ^eOther reasons for discontinuation among patients administered ATX were refusal to take medication (n = 1); patient relocation due to a family emergency (n = 1); and non-compliance (n = 1). ATX atomoxetine, FAS full analysis set, LDX lisdexamfetamine dimesylate